桂枝茯苓胶囊联合屈螺酮炔雌醇片治疗复发性卵巢子宫内膜异位囊肿的临床疗效研究  

Clinical Efficacy of Guizhi Fuling Capsules Combined with Drospirenone and Ethinylestradiol Tablets in the Treatment of Recurrent Ovarian Endometriosis Cysts

作　　者：王慧香[1] 彭悦 李书敏 王婧 WANG Huixiang;PENG Yue;LI Shumin;WANG Jing(Dept.of Obstetrics and Gynecology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院妇产科,北京100730

出　　处：《中国医院用药评价与分析》2021年第6期687-689,693,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：首都医科大学本科生创新项目(No.XSKY2021)。

摘　　要：目的:探讨桂枝茯苓胶囊联合屈螺酮炔雌醇片治疗复发性卵巢子宫内膜异位囊肿的临床疗效。方法:回顾性选取2018年1月至2021年1月在北京同仁医院就诊的复发性卵巢子宫内膜异位囊肿患者62例,根据用药情况分为对照组和观察组,每组31例。对照组患者于月经来潮第1日开始每晚睡前口服屈螺酮炔雌醇,连服21 d,停药7 d开始下1个周期;观察组患者在对照组的基础上于三餐后口服桂枝茯苓胶囊。两组患者均连续治疗6个月经周期。比较两组患者的临床疗效和用药安全性的差异,观察两组患者治疗前后的疼痛视觉模拟评分(visual analogue scale,VAS)、盆腔包块直径以及CA125水平。结果:观察组、对照组患者的总有效率分别为95.16%(59/62)、80.65%(50/62),观察组患者的临床疗效明显优于对照组,差异有统计学意义(P <0.05)。与治疗前相比,两组患者治疗后的VAS评分明显降低,盆腔包块直径明显缩小,CA125水平明显降低,且观察组患者上述指标明显优于对照组,差异均有统计学意义(P <0.05)。对照组、观察组患者的不良反应发生率分别为9.68%(6/62)、8.06%(5/62),差异无统计学意义(P> 0.05)。结论:桂枝茯苓胶囊联合屈螺酮炔雌醇片治疗复发性卵巢子宫内膜异位囊肿,可明显改善患者痛经和慢性盆腔痛,缩小盆腔包块直径,提高患者的生活质量,有一定的临床应用价值。OBJECTIVE: To probe into the clinical efficacy of Guizhi Fuling capsules combined with Drospirenone and ethinylestradiol tablets in the treatment of recurrent ovarian endometriosis cysts. METHODS: Totally 62 patients with recurrent ovarian endometriosis cysts admitted into Beijing Tongren Hospital from Jan. 2018 to Jan. 2021 were retrospectively extracted to be divided into the control group and the observation group according to different treatment regimens,with 31 cases in each group. The control group received Drospirenone and ethinylestradiol tablets at bedtime of every night on the first day of menstruation for 21 d,and the next cycle was started on the 7 th d after withdrawal.The observation group was given orally Guizhi Fuling capsules after three meals on the basis of the control group. Both groups were continuously treated for 6 menstrual cycles. Differences in clinical efficacy and medication safety between two groups were compared. The visual analogue scale( VAS),pelvic mass diameter and CA125 level were observed before and after treatment in two groups. RESULTS: The total effective rates in the observation group and the control group were respectively 95. 16%( 59/62) and 80. 65%( 50/62). The comparison of clinical efficacy showed that the observation group were significantly better than the control group,and the difference was statistically significant( P <0. 05). Compared with before treatment,after treatment,VAS score,pelvic mass diameter and CA125 level were decreased significantly in two groups,the above indicators in the observation group were significantly better than those in the control group,with statistically significant difference( P < 0. 05). The incidences of adverse drug reactions in the control and the observation groups were respectively 9. 68%( 6/62) and 8. 06%( 5/62),with no statistically significant difference( P > 0. 05). CONCLUSIONS: Guizhi Fuling capsules combined with Drospirenone and ethinylestradiol tablets in the treatment of recurrent ovarian endometriosis cysts can signific

关 键 词：桂枝茯苓胶囊 屈螺酮炔雌醇片 卵巢子宫内膜异位囊肿 复发 

分 类 号：R932[医药卫生—生药学]